Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Sueta

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
Journal of the American Heart Association|September 2, 2017
Prognostic Value of the CHADS<sub>2</sub> Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort StudyNoriaki Tabata, Eiichiro Yamamoto, Seiji Hokimoto, et al.
International Journal of Obesity (2005)|July 28, 2022
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary interventionYuichiro Shirahama, Noriaki Tabata, Kenji Sakamoto, et al.
Circulation|November 18, 2024
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Cardiovascular Intervention and Therapeutics|February 14, 2020
Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registryTakayoshi Yamashita, Kenji Sakamoto, Noriaki Tabata, et al.
Heart and Vessels|January 11, 2022
Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS)Khlood Ahmed, Yuichiro Arima, Noriaki Tabata, et al.
Cardiovascular Intervention and Therapeutics|January 9, 2021
Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort studyKenji Sakamoto, Ryota Sato, Noriaki Tabata, et al.
Journal of the American Heart Association|October 22, 2024
Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2Nobutaka Ikeda, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation|August 28, 2023
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical TrialYugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 22, 2024
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, et al.
Journal of the American Heart Association|September 30, 2024
Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral AnticoagulantsRyusuke Nishikawa, Yugo Yamashita, Takeshi Morimoto, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Journal of the American Heart Association|September 2, 2017
Prognostic Value of the CHADS<sub>2</sub> Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort StudyNoriaki Tabata, Eiichiro Yamamoto, Seiji Hokimoto, et al.
International Journal of Obesity (2005)|July 28, 2022
Validation of the obesity paradox by body mass index and waist circumference in patients undergoing percutaneous coronary interventionYuichiro Shirahama, Noriaki Tabata, Kenji Sakamoto, et al.
Circulation|November 18, 2024
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Cardiovascular Intervention and Therapeutics|February 14, 2020
Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registryTakayoshi Yamashita, Kenji Sakamoto, Noriaki Tabata, et al.
Heart and Vessels|January 11, 2022
Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS)Khlood Ahmed, Yuichiro Arima, Noriaki Tabata, et al.
Cardiovascular Intervention and Therapeutics|January 9, 2021
Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort studyKenji Sakamoto, Ryota Sato, Noriaki Tabata, et al.
Journal of the American Heart Association|October 22, 2024
Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2Nobutaka Ikeda, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation|August 28, 2023
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical TrialYugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 22, 2024
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, et al.
Journal of the American Heart Association|September 30, 2024
Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral AnticoagulantsRyusuke Nishikawa, Yugo Yamashita, Takeshi Morimoto, et al.
Pageof 18